|Application:||Gene expression microarray analysis|
|Number of samples:||12|
|Release date:||Feb 5 2018|
|Last update date:||Aug 23 2018|
|Diseases:||Leukemia, Leukemia, Hairy Cell, Philadelphia Chromosome, Genetic Predisposition to Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma|
|Dataset link||pre-B cells from normal control, preleukemic, fully leukemic and fully leukemic, nilotinib-treated P190 BCR/ABL transgenic mice|
Mice transgenic for the human P190 form of Bcr/Abl (Jackson Labs strain 017833) develop precursor B-lineage (pre-B) acute lymphoblastic leukemia, on average within 3 months of birth, when on a C57Bl/6J background. Bone marrows were isolated from control C57BLl/6J mice and from transgenic Bcr/Abl mice when they had not yet developed full-blown leukemia (90 days of age), and from fully leukemic mice that had received a seven-day treatment with 75 mg/kg AMN107 (nilotinib). Three mice were used per condition, and cells from each mouse were processed separately. Pre-B cells from these twelve bone marrows were flow-sorted using CD19 and AA4.1 as markers. Total RNA from CD19+ AA4.1+cells used for microarray analysis was isolated by RNeasy (QIAGEN) purification. Double-strand complementary DNA was generated from 5 µg of total RNA using a poly(dT) oligonucleotide that contains a T7 RNA polymerase initiation site and the SuperScript III reverse transcription (Invitrogen). Biotinylated cRNA was generated and fragmented according to the Affymetrix protocol and hybridized to 430 mouse microarrays (Affymetrix).